CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Stevanato Group Q3 revenue beats estimates on biopharma segment

By Reuters News


Overview

  • Italy drug containment and delivery firm's Q3 revenue grew 8%, beating analyst expectations

  • Adjusted diluted EPS for Q3 rose 14% to €0.16

  • Company maintained full-year 2026 guidance


Outlook

  • Stevanato Group maintains 2026 revenue guidance of €1.260 bln to €1.280 bln

  • Company expects 2026 adjusted EBITDA of €335.0 mln to €345.2 mln

  • Company anticipates low single-digit revenue growth in 2027 due to lower GLP-1 volumes


Result Drivers

  • BDS SEGMENT GROWTH - Organic revenue from Biopharmaceutical and Diagnostic Solutions rose 11%, driven by high-value and other containment and delivery solutions

  • ENGINEERING SEGMENT DECLINE - Revenue from the Engineering Segment fell 12%, mainly due to lower pharma visual inspection and assembly and packaging sales

  • GLP-1 REVENUE IMPACT - Lower GLP-1 therapy revenue was offset by over 30% growth in non-GLP-1 biologics demand, according to CEO Franco Stevanato


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

EUR 326.10 mln

EUR 320.93 mln (10 Analysts)

Q3 EPS

EUR 0.15

Q3 Net Income

EUR 41.80 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Stevanato Group SpA is $25.00, about 26.6% above its November 2 closing price of $19.74

  • The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 26 three months ago


Reuters Recommended Reads

  • Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises

  • Nov 3 - Biomérieux third-quarter organic sales growth beats expectations

  • Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.